Pfizer Settles $345M EpiPen Consumers Suit, But Viatris Marches On
Executive Summary
After four years of litigation, Pfizer has reached a preliminary settlement over allegations that it devised an “illegal scheme” with Viatris’ Mylan establish a monopoly for the EpiPen autoinjector device.